

# Information for Colorado Prescribers of Prescription Drugs Provided Pursuant to Colorado House Bill 19-1131

## **HEMLIBRA®** (emicizumab-kxwh)

<b><u>Marketed Drug</u></b>	<b><u>WAC Unit Price*</u></b>	<b><u>WAC Package Price*</u></b>
Hemlibra 30 mg/mL Vial	\$ 3,158.00 per mL	\$ 3,158.00 per vial
Hemlibra 60 mg/0.4 mL Vial	\$ 15,790.00 per mL	\$ 6,316.00 per vial
Hemlibra 105 mg/0.7 mL Vial	\$ 15,790.01428 per mL	\$ 11,053.01 per vial
Hemlibra 150 mg/mL Vial	\$ 15,790.01 per mL	\$ 15,790.01 per vial

### **Generic Drugs in Same Therapeutic Class\*\***

none

**\*Wholesale Acquisition Cost (WAC)** as published by FDB represents the manufacturer's published catalog or list price for a drug product to wholesalers as reported to FDB by the manufacturer. WAC does not represent actual transaction prices and does not include prompt pay or other discounts, rebates or reductions in price. FDB does not perform any independent investigation or analysis of actual transaction prices for purposes of reporting WAC. FDB relies on manufacturers to report or otherwise make available the values for the WAC.

For more information about First Databank's drug pricing policy, visit  
<https://www.fdbhealth.com/drug-pricing-policy>

**\*\*The USC (Uniform System of Classification)** Therapeutic Classification schema was used to determine similar generic drugs. The **HCFA Drug Category of "Non-Innovator Multi-source"** as supplied on the CMS (formerly HCFA) quarterly update was used to determine the generic status of the drug products.

Source: AnalySource® 1/5/2022 as reprinted with permission by First Databank, Inc. All rights reserved. ©2022

M-US-00002942(v3.0)